Cargando…

A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer

The optimal management of patients with oligorecurrent prostate cancer (PCa) is unknown. There is growing interest in metastasis-directed therapy (MDT) for this population. The objective was to assess cost-utility from a Belgian healthcare payer’s perspective of MDT and delayed androgen deprivation...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Bleser, Elise, Willems, Ruben, Decaestecker, Karel, Annemans, Lieven, De Bruycker, Aurélie, Fonteyne, Valérie, Lumen, Nicolaas, Ameye, Filip, Billiet, Ignace, Joniau, Steven, De Meerleer, Gert, Ost, Piet, Bultijnck, Renée
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016808/ https://www.ncbi.nlm.nih.gov/pubmed/31947974 http://dx.doi.org/10.3390/cancers12010132

Ejemplares similares

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
por: Decaestecker, Karel, et al.
Publicado: (2014)

Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer
por: Fonteyne, Valérie, et al.
Publicado: (2012)

Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome
por: Claeys, Tom, et al.
Publicado: (2015)

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial
por: De Wolf, Katrien, et al.
Publicado: (2017)

The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study
por: Poelaert, Filip, et al.
Publicado: (2015)

Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial
por: Fonteyne, Valérie, et al.
Publicado: (2017)

Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial
por: Draulans, Cédric, et al.
Publicado: (2018)

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
por: Lumen, Nicolaas, et al.
Publicado: (2021)

Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol
por: Rammant, Elke, et al.
Publicado: (2017)

Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients
por: Huysse, Wouter, et al.
Publicado: (2017)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy
por: Devos, Gaëtan, et al.
Publicado: (2020)

Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?
por: Zilli, Thomas, et al.
Publicado: (2018)

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
por: Deek, Matthew P., et al.
Publicado: (2022)

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
por: Rans, Kato, et al.
Publicado: (2022)

Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
por: Berkovic, Patrick, et al.
Publicado: (2020)

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial
por: Verghote, Flor, et al.
Publicado: (2021)

PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial
por: De Bruycker, A., et al.
Publicado: (2020)

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy
por: De Wolf, Katrien, et al.
Publicado: (2015)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Perineal Urethrostomy: Surgical and Functional Evaluation of Two Techniques
por: Lumen, Nicolaas, et al.
Publicado: (2015)

Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and 2 in a Cohort of 245 Patients with Histopathological Reference and Long-Term Follow-Up
por: De Visschere, Pieter, et al.
Publicado: (2016)

Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?
por: Helsmoortel, Hetty, et al.
Publicado: (2018)

Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!
por: Van Praet, Charles, et al.
Publicado: (2021)

Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial
por: Lorton, Orane, et al.
Publicado: (2023)

Anastomotic Repair versus Free Graft Urethroplasty for Bulbar Strictures: A Focus on the Impact on Sexual Function
por: Beysens, Matthias, et al.
Publicado: (2015)

Phase III randomised chemoprevention study of Selenium on the recurrence of non-invasive bladder cancer. The SELEnium and BLAdder cancer Trial (SELEBLAT)
por: Goossens, Maria (Mieke), et al.
Publicado: (2015)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

Selecting candidates for early discharge after radical cystectomy for bladder cancer
por: Fonteyne, Valérie, et al.
Publicado: (2018)

Perspective on cytoreduction and metastasis-directed therapy in node positive and metastatic urothelial carcinoma of the bladder
por: Decaestecker, Karel, et al.
Publicado: (2017)

Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis
por: Vermassen, Tijl, et al.
Publicado: (2015)

Nine-year survival after iterative metastasectomies for renal cell carcinoma
por: de Oliveira, Tiago Ribeiro, et al.
Publicado: (2019)

Node Oligorecurrence in Prostate Cancer: A Challenge
por: Zapatero, Almudena, et al.
Publicado: (2023)

Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease
por: Macagno, Alban, et al.
Publicado: (2022)

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
por: Sundahl, Nora, et al.
Publicado: (2017)

Intensity modulated radiotherapy induces pro-inflammatory and pro-survival responses in prostate cancer patients
por: EL-SAGHIRE, HOUSSEIN, et al.
Publicado: (2014)

Primary versus Redo Urethroplasty: Results from a Single-Center Comparative Analysis
por: Verla, Wesley, et al.
Publicado: (2020)

The equity dimension in evaluations of the quality and outcomes framework: A systematic review
por: Boeckxstaens, Pauline, et al.
Publicado: (2011)

Lung Radiofrequency Ablation: Potential as a Therapy to Oligometastasis and Oligorecurrence
por: Hiraki, Takao, et al.
Publicado: (2012)

Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
por: Berghen, Charlien, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7msspql8g1sg7gprhpueo4dhju